Abrogation of tumor vasculature using gene therapy.
Anti-angiogenic gene therapy may be a rational approach in the treatment of solid tumors. The current state of gene therapy with regard to the abrogation of tumor vasculature is reviewed in this article and the different administration vehicles are noted. Furthermore, this article discusses the influence of vascular support cells in the tumor vasculature and choice of pre-clinical model for anti-angiogenic cancer gene therapy.
Nesbit
M
M
Aventis-Gencell, Department of Antiangiogenesis, Hayward, California 94545, USA. nesbit.mark@rp-rorer.com
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D003094:Collagen / Q000627:therapeutic use; D043169:Endostatins; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010446:Peptide Fragments / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D010446:Peptide Fragments; D003094:Collagen